BURLINGTON, Mass., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that
it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common
stock. Flexion also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in the
public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or
terms of the offering.
Wells Fargo Securities, RBC Capital Markets and BMO Capital Markets are acting as joint book-running managers.
The shares of common stock described above are being offered pursuant to a shelf registration statement previously filed with
and declared effective by the Securities and Exchange Commission (SEC). A preliminary prospectus supplement and accompanying
prospectus relating to the offering have been filed with the SEC and are available for free on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus
relating to the offering may also be obtained from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park
Avenue, New York, New York 10152, or by email at cmclientsupport@wellsfargo.com, or by telephone at (800) 326-5897; from RBC Capital Markets,
LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281, or by telephone at (877) 822-4089, or by email
at equityprospectus@rbccm.com; or from BMO Capital Markets Corp., 3 Times Square, 25th Floor, New
York, NY 10036, Attention: Equity Syndicate Department, or by telephone at (800) 414-3627, or by email at bmoprospectus@bmo.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of Flexion’s securities. No
offer, solicitation or sale will be made in any state or other jurisdiction in which such offer, solicitation or sale would be
unlawful.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the
treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate,
Zilretta, is being investigated for its potential to provide improved analgesic therapy for the millions of U.S. patients who
receive intra-articular (IA) injections for knee OA annually.
Forward-Looking Statements
Statements in this press release regarding matters that are not historical facts, including, but not limited to, statements
relating to expectations regarding the completion and timing of our proposed public offering, are forward-looking statements. These
forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are
subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied
by such statements. These risks and uncertainties include, without limitation, risks associated with market conditions and the
satisfaction of customary closing conditions related to the proposed offering, as well as other risks and uncertainties described
in our filings with the SEC, including under the heading "Risk Factors" in our most recent Annual Report on Form 10-K and
subsequent filings with the SEC. The forward-looking statements in this press release speak only as of the date of this press
release, and we undertake no obligation to update or revise any of the statements. We caution investors not to place considerable
reliance on the forward-looking statements contained in this press release.
Investor Contact David Carey Lazar Partners LTD T: 212-867-1768 dcarey@lazarpartners.com Media Contact Danielle Lewis Lazar Partners LTD T: 212-843-0211 dlewis@lazarpartners.com Corporate Contact Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 fdriscoll@flexiontherapeutics.com
